Class summary at a glance.

Every drug in the Central alpha-2 Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $138.5Mcombined across class
Total Rx claims: 6.4M1.9M unique beneficiaries
Generic mfrs (active): 65across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Clonidine

Brand: Duraclon · 6.0M Part D claims (CY24) · 1.8M beneficiaries · First FDA approval: 1987-09-04

23 generic mfrs 6 plans require PA

Low NADAC$0.025

→

Avg plan cost$2.24

Part D spend $123.7M 89× spread, current vs floor

Class share

89%

of class CY24 spend

View profile →

Guanfacine

Brand: GUANFACINE · 398K Part D claims (CY24) · 89K beneficiaries · First FDA approval: 1995-10-17

18 generic mfrs 412 plans require PA Discontinued

Low NADAC$0.140

→

Avg plan cost$0.740

Part D spend $14.4M 5× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Dexmedetomidine

Brand: Dexmedetomidine Hydrochloride in Sodium Chloride · 97 Part D claims (CY24) · 42 beneficiaries · First FDA approval: 2004-11-30

24 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend $308999

Class share

of class CY24 spend

View profile →

Clonidine Transdermal System

Brand: Catapres-TTS-1 · — Part D claims (CY24) · First FDA approval: 2022-03-01

Brand-only (no generics)

Low NADAC$7.23

→

Avg plan cost$9.43

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Dexmedetomidine Hydrochloride In

Brand: Dexmedetomidine Hydrochloride · — Part D claims (CY24) · First FDA approval: 2019-08-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.